COVID-19: Pfizer-BioNTech tests third dose of vaccine against new SARS-CoV-2 variants. The study is part of clinical development.
Pamela Cruz. Pen sula 360 Press [P360P].
Pfizer and BioNTech announced Thursday that they have begun an evaluation of the safety and ability of their antibody to activate the immune system and induce an immune response (immunogenicity) with a third dose of their COVID-19 vaccine, following strong concerns about variants of the SARS-CoV-2 virus.
Through a statement, Pfizer said that these tests